Synthesis and antibacterial evaluation of new, unsymmetrical triaryl bisamidine compounds. 2014

Son T Nguyen, and John D Williams, and Michelle M Butler, and Xiaoyuan Ding, and Debra M Mills, and Tommy F Tashjian, and Rekha G Panchal, and Susan K Weir, and Chaeho Moon, and Hwa-Ok Kim, and Jeremiah A Marsden, and Norton P Peet, and Terry L Bowlin
Microbiotix, Inc., 1 Innovation Drive, Worcester, MA 01604, USA. Electronic address: snguyen@microbiotix.com.

Herein we describe the synthesis and antibacterial evaluation of a new, unsymmetrical triaryl bisamidine compound series, [Am]-[indole]-[linker]-[HetAr/Ar]-[Am], in which [Am] is an amidine or amino group, [linker] is a benzene, thiophene or pyridine ring, and [HetAr/Ar] is a benzimidazole, imidazopyridine, benzofuran, benzothiophene, pyrimidine or benzene ring. When the [HetAr/Ar] unit is a 5,6-bicyclic heterocycle, it is oriented such that the 5-membered ring portion is connected to the [linker] unit and the 6-membered ring portion is connected to the [Am] unit. Among the 34 compounds in this series, compounds with benzofuran as the [HetAr/Ar] unit showed the highest potencies. Introduction of a fluorine atom or a methyl group to the triaryl core led to the more potent analogs. Bisamidines are more active toward bacteria while the monoamidines are more active toward mammalian cells (as indicated by low CC50 values). Importantly, we identified compound P12a (MBX 1887) with a relatively narrow spectrum against bacteria and a very high CC50 value. Compound P12a has been scaled up and is currently undergoing further evaluations for therapeutic applications.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Son T Nguyen, and John D Williams, and Michelle M Butler, and Xiaoyuan Ding, and Debra M Mills, and Tommy F Tashjian, and Rekha G Panchal, and Susan K Weir, and Chaeho Moon, and Hwa-Ok Kim, and Jeremiah A Marsden, and Norton P Peet, and Terry L Bowlin
April 2014, European journal of medicinal chemistry,
Son T Nguyen, and John D Williams, and Michelle M Butler, and Xiaoyuan Ding, and Debra M Mills, and Tommy F Tashjian, and Rekha G Panchal, and Susan K Weir, and Chaeho Moon, and Hwa-Ok Kim, and Jeremiah A Marsden, and Norton P Peet, and Terry L Bowlin
November 2020, Bioorganic & medicinal chemistry letters,
Son T Nguyen, and John D Williams, and Michelle M Butler, and Xiaoyuan Ding, and Debra M Mills, and Tommy F Tashjian, and Rekha G Panchal, and Susan K Weir, and Chaeho Moon, and Hwa-Ok Kim, and Jeremiah A Marsden, and Norton P Peet, and Terry L Bowlin
May 2024, Scientific reports,
Son T Nguyen, and John D Williams, and Michelle M Butler, and Xiaoyuan Ding, and Debra M Mills, and Tommy F Tashjian, and Rekha G Panchal, and Susan K Weir, and Chaeho Moon, and Hwa-Ok Kim, and Jeremiah A Marsden, and Norton P Peet, and Terry L Bowlin
March 2022, Bioorganic & medicinal chemistry,
Son T Nguyen, and John D Williams, and Michelle M Butler, and Xiaoyuan Ding, and Debra M Mills, and Tommy F Tashjian, and Rekha G Panchal, and Susan K Weir, and Chaeho Moon, and Hwa-Ok Kim, and Jeremiah A Marsden, and Norton P Peet, and Terry L Bowlin
December 2015, Molecules (Basel, Switzerland),
Son T Nguyen, and John D Williams, and Michelle M Butler, and Xiaoyuan Ding, and Debra M Mills, and Tommy F Tashjian, and Rekha G Panchal, and Susan K Weir, and Chaeho Moon, and Hwa-Ok Kim, and Jeremiah A Marsden, and Norton P Peet, and Terry L Bowlin
May 2021, Bioorganic & medicinal chemistry letters,
Son T Nguyen, and John D Williams, and Michelle M Butler, and Xiaoyuan Ding, and Debra M Mills, and Tommy F Tashjian, and Rekha G Panchal, and Susan K Weir, and Chaeho Moon, and Hwa-Ok Kim, and Jeremiah A Marsden, and Norton P Peet, and Terry L Bowlin
January 2023, Pharmaceuticals (Basel, Switzerland),
Son T Nguyen, and John D Williams, and Michelle M Butler, and Xiaoyuan Ding, and Debra M Mills, and Tommy F Tashjian, and Rekha G Panchal, and Susan K Weir, and Chaeho Moon, and Hwa-Ok Kim, and Jeremiah A Marsden, and Norton P Peet, and Terry L Bowlin
January 2018, Mini reviews in medicinal chemistry,
Son T Nguyen, and John D Williams, and Michelle M Butler, and Xiaoyuan Ding, and Debra M Mills, and Tommy F Tashjian, and Rekha G Panchal, and Susan K Weir, and Chaeho Moon, and Hwa-Ok Kim, and Jeremiah A Marsden, and Norton P Peet, and Terry L Bowlin
December 2014, Journal of enzyme inhibition and medicinal chemistry,
Son T Nguyen, and John D Williams, and Michelle M Butler, and Xiaoyuan Ding, and Debra M Mills, and Tommy F Tashjian, and Rekha G Panchal, and Susan K Weir, and Chaeho Moon, and Hwa-Ok Kim, and Jeremiah A Marsden, and Norton P Peet, and Terry L Bowlin
July 2019, BMC complementary and alternative medicine,
Copied contents to your clipboard!